GeneDx Holdings Corp. (WGS)

NASDAQ: WGS · IEX Real-Time Price · USD
22.39
-1.63 (-6.79%)
At close: May 17, 2024, 4:00 PM
23.03
+0.64 (2.86%)
After-hours: May 17, 2024, 7:45 PM EDT
-6.79%
Market Cap 591.14M
Revenue (ttm) 221.85M
Net Income (ttm) -135.02M
Shares Out 26.15M
EPS (ttm) -5.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 298,436
Open 23.85
Previous Close 24.02
Day's Range 22.27 - 24.40
52-Week Range 1.16 - 24.40
Beta 2.26
Analysts Strong Buy
Price Target 18.00 (-19.61%)
Earnings Date Apr 29, 2024

About WGS

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Cor... [Read more]

Sector Healthcare
Founded 2017
Employees 1,000
Stock Exchange NASDAQ
Ticker Symbol WGS
Full Company Profile

Financial Performance

In 2023, WGS's revenue was $202.57 million, a decrease of -13.69% compared to the previous year's $234.69 million. Losses were -$175.77 million, -67.98% less than in 2022.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for WGS stock is "Strong Buy." The 12-month stock price forecast is $18.0, which is a decrease of -19.61% from the latest price.

Price Target
$18.0
(-19.61% downside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

GeneDx Reports First Quarter 2024 Financial Results and Business Highlights

Reported first quarter 2024 revenue from continuing operations 1 of $61.5M with 96% year-over-year growth of exome and genome test revenue Expanded first quarter 2024 adjusted gross margins 2 from con...

19 days ago - GlobeNewsWire

GeneDx Announces Partnership with Komodo Health to Expand Access to World's Largest Rare Disease Dataset

The Company will also participate in a World Orphan Drug Congress panel presentation highlighting the role of genomic sequencing in advancing precision medicine The Company will also participate in a ...

25 days ago - GlobeNewsWire

GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024

Management will host a conference call on Monday, April 29, 2024 to discuss first quarter 2024 financial and operating results at 4:30 p.m. Eastern Time.

6 weeks ago - GlobeNewsWire

GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics

STAMFORD, Conn., March 14, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the ...

2 months ago - GlobeNewsWire

GeneDx to Participate in 44th Annual Cowen Health Care Conference

STAMFORD, Conn., Feb. 26, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management ...

2 months ago - GlobeNewsWire

GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024

Reported fourth quarter 2023 revenue from continuing operations 1 of $58.1M with more than 68% year-over-year growth of exome and genome test revenue Expanded fourth quarter 2023 adjusted gross margin...

3 months ago - GlobeNewsWire

GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024

GeneDx management will host a conference call at 4:30 p.m. Eastern Time on February 20, 2024 to discuss 2023 results and share full year 2024 guidance.

3 months ago - GlobeNewsWire

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

STAMFORD, Conn., Jan. 24, 2024 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of January 23, 2024...

4 months ago - GlobeNewsWire

GeneDx Announces Preliminary 2023 Financial Results

Expects to exceed revised 2023 revenue guidance with fourth quarter 2023 revenue from continuing operations1 of more than $57M with at least 63% year-over-year revenue growth for exome and genome test...

4 months ago - GlobeNewsWire

GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy

New research from one of the largest exome sequencing studies of patients with epilepsy adds to the mounting evidence that exome sequencing offers superior clinical results compared to multi-gene pane...

6 months ago - GlobeNewsWire

GeneDx to Participate in 6th Annual Evercore ISI HealthCONx Conference

STAMFORD, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management ...

6 months ago - GlobeNewsWire

GeneDx Reports Third Quarter 2023 Financial Results and Business Highlights

Reported total revenue of $53M with more than 40% year-over-year growth of exome and genome test revenue

7 months ago - GlobeNewsWire

GeneDx to Report Third Quarter 2023 Financial Results on Monday, October 30, 2023

STAMFORD, Conn., Oct. 09, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financia...

7 months ago - GlobeNewsWire

GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in Genetics in Medicine

STAMFORD, Conn., Aug. 21, 2023 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that Genetics in Medicine, the officia...

9 months ago - GlobeNewsWire

PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care

Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platforms  MENLO PARK, Calif. and STAMFORD, Conn.

Other symbols: PACB
10 months ago - PRNewsWire

GeneDx and Prognos Health Announce Strategic Partnership to Help Rare Disease Patients More Rapidly Gain Access to Potential Treatment Options

Partnership allows commercial biopharma companies to leverage real-time data within comprehensive Prognos Marketplace to provide available treatment options for patients Partnership allows commercial ...

10 months ago - GlobeNewsWire

GeneDx to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

STAMFORD, Conn., July 18, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financia...

10 months ago - GlobeNewsWire

GeneDx to Present New Data on Urine Mitochondrial DNA Testing at the 2023 United Mitochondrial Disease Foundation's Mitochondrial Medicine Symposium

STAMFORD, Conn., June 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will present new data...

11 months ago - GlobeNewsWire

GeneDx Announces New Tool to Help Harness Human Pangenome Diversity for Clinical Interpretation of Variants

N ew paper published today in Nature Methods describes the PanGenome Research-Tool Kit for analyz ing complex regions of the human pan genome

11 months ago - GlobeNewsWire

GeneDx Commends the States of Arizona and Florida for Adding Rapid Whole Genome Sequencing (rWGS) as a Covered Benefit for Medicaid Pediatric Patients

Eight state Medicaid programs now cover rWGS in the pediatric inpatient setting, with active bills in other states Eight state Medicaid programs now cover rWGS in the pediatric inpatient setting, with...

11 months ago - GlobeNewsWire

GeneDx to Participate in World Orphan Drug Congress Keynote and Panel Presentations

Keynote session to highlight value of GeneDx genomic data and clinical insights to accelerate genetic neurodevelopmental disorder pipeline for Mahzi Therapeutics Keynote session to highlight value of ...

1 year ago - GlobeNewsWire

GeneDx Regains Compliance with Nasdaq Minimum Bid Price Requirement

STAMFORD, Conn., May 22, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that it had received a le...

1 year ago - GlobeNewsWire

GeneDx Adds Buccal Swab as Non-Invasive Whole Genome Sequencing Sample Collection Option

New Option Enables Easier DNA Sample Collection from Biological Parents to Aid in Disease Diagnosis New Option Enables Easier DNA Sample Collection from Biological Parents to Aid in Disease Diagnosis

1 year ago - GlobeNewsWire

GeneDx Announces Clarification Regarding CUSIP Number for Public Warrant Holders

STAMFORD, Conn., May 03, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced a clarification regarding...

1 year ago - GlobeNewsWire

GeneDx Announces Reverse Stock Split

STAMFORD, Conn., April 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that its board of direc...

1 year ago - GlobeNewsWire